Synthesis of C-nucleosidic ATP mimics as potential FGFR3 inhibitors

European Journal of Organic Chemistry

Volumn , Issue 10, 2006, Pages 2403-2409

  Busca, Patricia ^a   McCort, Isabelle ^a   Prangé, Thierry ^a   Le Merrer, Yves ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

D Mannitol; Heterocycles; Nucleosides; Tyrosine kinase inhibitors

Indexed keywords

EID: 33646743202     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200500999     Document Type: Article

References (25)

1. a) D. J. Stauber, A. D. DiGabriele, W. A. Hendrickson, Proc. Natl. Acad. Sci. USA 2000, 97, 49-54;
2. b) A. Kurup, R. Garg, C. Hansch, Chem. Rev. 2001, 101, 2573-2600;
3. c) F. Manetti, M. Botta, Curr. Pharm. Des. 2003, 9, 399-409.
4. D. Cappellen, C. de Oliveira, D. Ricol, S. De Medina, J. Bourdin, X. Sastre-Garau, D. Chopin, J.-P. Thiery, F. Radvanyi, Nature Genet. 1999, 23, 18-20.
5. J. Bonaventure, F. Rousseau, L. Legeai-Mallet, M. Le Merrer, A. Munnich, P. Maroteaux, Am. J. Med. Genet. 1996, 63, 148-164.
6. P. Traxler, Exp. Opin. Ther. Pat. 1998, 8, 1599-1625.
7. S. Rigolet, I. McCort, Y. Le Merrer, Tetrahedron Lett. 2002, 43, 8129-8132.
8. a) L. Kaverno, R. Kumar, B. M. Dahl, C. E. Olsen, J. Wengel, J. Org. Chem. 2000, 65, 5167-5176;
9. b) Z. J. Yang, H. W. Yu, J. M. Min, L. T. Ma, L. H. Zhang, Tetrahedron: Asymmetry 1997, 8, 2739-2747;
10. c) B. Doboszewski, Nucleosides Nucleotides 1997, 16, 1049-1052.
11. A. E. Wróblewski, W. Karolczak, Tetrahedron 2003, 59, 6075-6081.
12. a) M. W. Winkley, Carbohydr. Res. 1973, 31, 245-254;
13. b) M. Bobek, J. Farkas, Coll. Czech. Chem. Commun. 1969, 34, 1684-1691.
14. L. Poitout, Y. Le Merrer, J.-C. Depezay, Tetrahedron Lett. 1994, 35, 3293-3296.
15. F. Roussel, N. Moitessier, M. Hilly, F. Chrétien, J.-P. Mauger, Y. Chapleur, Bioorg. Med. Chem. 2002, 10, 759-768.
16. a) A. J. Jones, D. M. Grant, M. W. Winkley, R. K. Robins, J. Am. Chem. Soc. 1970, 92, 4079-4087;
17. b) S. Raić-Malić, A. Hergold-Brundić, A. Nagl, M. Grdiša, K. Pavelić, E. De Clercq, M. Mintas, J. Med. Chem. 1999, 42, 2673-2678.
18. J. C. Martin, D. F. Smee, J. P. H. Verheyden, J. Org. Chem. 1985, 50, 755-759.
19. G. M. Sheldrick, SHELXL 97, program for the refinement of crystal structures, Göttingen, Germany, 1997.
20. R. Saladino, U. Ciambecchini, S. Hanessian, Eur. J. Org. Chem. 2003, 4401-4405.
21. [14]. For example in Scheme 1 bis-epoxide 3 and related compounds 4-9 are described with a L-manno and a D-gulo configuration, respectively, instead of a O-manno or a L-gulo configuration, and in Scheme 2 there should be an L-gulo configuration for compounds 13-18.
22. a) V. Kryštof, R. Lenobel, L. Havliček, M. Kuzma, M. Strnad, Bioorg. Med. Chem. Lett. 2002, 12, 3283-3286;
23. b) M. T. Crimmins, W. I. Zuercher, Org. Lett. 2000, 2, 1065-1067;
24. c) S. G. Petersen, S. R. Rajski, J. Org. Chem. 2005, 70, 5833-5839;
25. d) S. R. Schow, R. L. Mackman, C. L. Blum, E. Brooks, A. G. Horsma, A. Joly, S. S. Kerwar, G. Lee, D. Shiffman, M. G. Nelson, X. Wang, M. M. Wick, X. Zhang, R. T. Lum, Bioorg. Med. Chem. Lett. 1997, 7, 2697-2702.